

Pyrimidine Derivatives. XI.¹⁾ Facile Carbon–Carbon Bond-Cleavage Reaction of 6-Bromomethylpyrimidinediones and (2,4-Dioxo-1,2,3,4-tetrahydropyrimidin-6-yl)methyl Nitrate via 6-Formyl Derivatives

Toshio KINOSHITA,* Hiroshi OHISHI, and Youko TANIMOTO

School of Pharmaceutical Sciences, Nagasaki University, 1–14 Bunkyo-machi, Nagasaki 852, Japan.

Received March 22, 1993

The reaction of 5-bromo-6-bromomethyl-1,3-dimethyl- (1a) and 5-bromo-6-bromomethyl-1-(3-bromopropyl)-3-methyl-2,4(1*H*,3*H*)-pyrimidinedione (4a) with 1.0 and 2.0 eq of the sodium salt of 2-nitropropane yielded a mixture of 6-formyl (2 and 5a) and carbon–carbon bond-cleavage products (3 and 6a). When a large excess of the sodium salt of 2-nitropropane was used, 3 and 6a were obtained as sole products, respectively. The nitrates [(5-bromo-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-6-yl)methyl nitrate (1b) and the dinitrate of 5-bromo-6-hydroxymethyl-1-(3-hydroxypropyl)-3-methyl-2,4(1*H*,3*H*)-pyrimidinedione (4b)] were exclusively converted to 6-formylpyrimidines (2 and 5b) or 6-unsubstituted pyrimidinediones (3 and 6b) by reaction with 1.0 or 2.0 eq of sodium methoxide, respectively. The dinitrate of 5-bromo-1-(2-hydroxyethyl)-6-hydroxymethyl-3-methyl-2,4(1*H*,3*H*)-pyrimidinediones (7) was treated with sodium methoxide to yield 2-(5-bromo-6-formyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)ethyl nitrate (8), a 3,4-dihydropyrimido[6,1-*c*][1,4]oxazine derivative (9) and 2-(5-bromo-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)ethyl nitrate (10). A plausible reaction mechanism is presented.

Keywords deformylation; (pyrimidin-6-yl)methyl nitrate; 6-bromomethylpyrimidine; 6-formylpyrimidine; reaction mechanism

Allylic and benzylic halides can be readily converted to the corresponding aldehydes by treatment with alkali metal salts of nitroalkanes.²⁾ In a previous paper,³⁾ we applied this method for the preparation of a 3,4-dihydropyrimido[6,1-*c*][1,4]oxazine derivative (9),⁴⁾ by treatment of 5-bromo-1-(2-bromoethyl)-6-bromomethyl-3-methyl-2,4(1*H*,3*H*)-pyrimidinedione with the sodium salt of 2-nitropropane. The same bicyclic compound (9) was also prepared by reaction of the dinitrate of 5-bromo-1-(3-hydroxyethyl)-6-hydroxymethyl-3-methyl-2,4(1*H*,3*H*)-pyrimidinedione (7)⁴⁾ with sodium methoxide. However, when 5-bromo-1-(3-bromopropyl)-6-bromomethyl-3-methyl-2,4(1*H*,3*H*)-pyrimidinedione (4a)⁵⁾ reacted with the sodium salt of 2-nitropropane under the same conditions described in the previous paper,³⁾ the resulting product was 5-bromo-1-(3-bromopropyl)-3-methyl-2,4(1*H*,3*H*)-pyrimidinedione, which is apparently to the debromomethylation product of the starting material.

Decarboxylation is an important reaction in the chemistry of nitrogen heterocyclic compounds⁶⁾ (e.g., pyridine-, quinoline-, isoquinoline-, and pyrimidinecarboxylic acids) for the removal of alkyl groups, which are often introduced

during primary synthesis. However, this procedure requires a high temperature (180–250 °C or higher), and the products are obtained in low yields.

In this paper, we describe a carbon–carbon (C–C) bond-cleavage reaction of 6-bromomethyl-2,4-pyrimidinediones by treatment with the sodium salt of 2-nitropropane and that of (pyrimidin-6-yl)methyl nitrate with sodium methoxide. This type of reaction should be useful as a new C–C bond-cleavage reaction for the removal of unwanted functional groups (e.g., methyl, hydroxymethyl, halogenomethyl, methyl nitrate) under mild reaction conditions and in high yields.

Results and Discussion

6-Bromomethyl Derivatives When 5-bromo-6-bromomethyl-1,3-dimethyl-2,4(1*H*,3*H*)-pyrimidinedione (1a)⁷⁾ was treated with 1.0 and 2.0 eq of the sodium salt of 2-nitropropane, 5-bromo-1,3-dimethyl-6-formyl- (2) and 5-bromo-1,3-dimethyl-2,4(1*H*,3*H*)-pyrimidinedione (3)⁸⁾ were isolated (Table I, entries 1 and 2). The yield of the C–C bond-cleavage product (3) increased with increase in the molar ratio of the sodium salt of 2-nitropropane. When 4.0 eq of the sodium salt of 2-nitropropane was used, 3 was

TABLE I. Reactions^{a)} of 1a and 4a with Sodium Methoxide and 2-Nitropropane

Entry No.	Compound			Sodium methoxide (eq)	2-Nitropropane (eq)	Yield (g%)	Product (ratio in %)		
	No.	(eq)	(g)				1a	2/5a	3/6a
1	1a	1.0	0.63	1.0	1.0	0.43	24	64	12
2	1a	1.0	0.63	2.0	2.0	0.41	—	36	64
3	1a	1.0	0.63	4.0	4.0	0.35 (80)	—	—	100
4	4a	1.0	1.26	1.0	1.0	0.75	—	60	40
5	4a	1.0	1.26	2.0	2.0	0.73 (75)	—	—	100
6	4a	1.0	1.26	4.0	4.0	0.83 (85)	—	—	100

a) The reaction procedure and computation of product ratio are described in the experimental section.




Chart 1

TABLE II. Reactions^{a)} of **1b** and **4b** with Sodium Methoxide

Entry No.	Compound		Sodium methoxide (eq)	Product (ratio in %)		
	No.	(g)		Yield (g%)	2/5b	3/6b
1	1b	1.0	0.88	1.0	0.58 (78)	100 —
2	1b	1.0	0.88	2.0	0.59 (80)	— 100
3	4b	1.0	0.77	1.0	0.51 (82)	100 —
4	4b	1.0	0.77	2.0	0.45 (73)	— 100
5	4b	1.0	0.77	4.0	0.40 (65)	— 100
6 ^{b)}	4b	1.0	0.77	4.0	0.48 (78)	— 100

a) The reaction procedure and computation of product ratio are described in the experimental section. b) The reaction was carried out at 0°C for 3 h.

obtained exclusively (entry 3). In the case of 5-bromo-6-bromomethyl-1-(3-bromopropyl)-3-methyl-2,4(1*H*,3*H*)-pyrimidinedione (**4a**), a mixture of **5a** and **6a** was obtained in a 6:4 ratio, even when 1.0 eq of the sodium salt of 2-nitropropane was used (entry 4). The C–C bond-cleaved compound (**6a**) was isolated as a sole product when 2.0 or 4.0 eq of the sodium salt of 2-nitropropane was used (entries 5 and 6).

6-Pyrimidinylmethyl Nitrates When the nitrates (**1b** and **4b**⁴⁾ were treated with 1.0 eq of sodium methoxide, the 6-formyl compounds (**2** and **5b**) were obtained exclusively (Table II, entries 1 and 3). On the other hand, when more than 2.0 eq of sodium methoxide was used, the C–C bond-cleaved compounds (**3** and **6b**) were obtained as sole


TABLE III. Reactions^{a)} of **7** and **8** with Sodium Methoxide

Entry No.	Compound		Sodium methoxide (eq)	Product (ratio in %)		
	No.	(g)		Yield (g)	8	9
1	7	1.0	0.74	1.0	0.43	100 — —
2	7	1.0	0.74	1.5	0.59	8 69 23
3	7	1.0	0.74	2.0	0.49	— 76 24
4	7	1.0	0.74	3.0	0.54	— 75 25
5 ^{b)}	7	1.0	0.74	2.0	0.52	— 71 29
6	8	1.0	0.64	0.5	0.61	13 65 22
7 ^{c)}	8	1.0	0.64	0.5	0.56	7 71 22
8	8	1.0	0.64	1.0	0.55	— 79 21

a) The reaction procedure and computation of products ratio are described in the experimental section. b) The reaction was carried out at 60–65°C for 1 h. c) The reaction was carried out at room temperature for 12 h.

products, respectively (entries 2, 4, 5, and 6). As the reactions of the dinitrate (**7**) with sodium methoxide have been described previously,³⁾ the reactions were reexamined in detail and the results are summarized in Table III. When 1.0 eq of sodium methoxide was used, the 6-formyl compound (**8**) was obtained as a sole product in 66% yield (entry 1). Three compounds, *i.e.*, 6-formyl (**8**), bicyclic (**9**), and C–C bond-cleaved compounds (**10**), were identified when 1.5 eq of sodium methoxide was used (entry 2). More than 2.0 eq of sodium methoxide gave nearly the same product ratio as shown in entries 3 and 4. A slight temperature dependence was observed in the product ratio (entry

step 1



step 2




Chart 2

5).

From the above results, the 6-formyl compound (**8**) was regarded as the intermediate for the bicyclic (**9**) and the C-C bond-cleaved products (**10**). Therefore, the 6-formyl compound (**8**) was treated with sodium methoxide under various conditions as shown in Table III. In all cases, the C-C bond-cleaved product (**10**) was obtained in the same ratio (entries 6, 7, and 8). The ratio of the bicyclic compound (**9**) increased with an increase in the molar ratio of sodium methoxide (entry 8). Similarly, compound **10** was obtained in 91% yield from **7** under phase transfer-catalyzed conditions: tetraethylammonium chloride/sodium hydroxide in chloroform system.

Reaction Mechanisms On the basis of the above-mentioned results, a plausible reaction mechanism is presented in Chart 2. Initially, the methoxide ion attacks the hydrogen of the 6- CH_2ONO_2 group, then the hydrogen atom is removed followed by the loss of methanol and nitrite anion (as NaNO_2) to give the 6-formyl compound (**8**) (step 1: in this step, 1.0 eq of sodium methoxide is consumed). The second methoxide ion (excess anion) attacks the formyl carbon, and at this point the reaction pathway separates into routes A and B, which must be in competition (step 2).

If the compound possesses a good leaving group (such as bromine or $-\text{ONO}_2$) at the β -carbon of the 1-substituent, the oxygen atom of the carbonyl moiety (intermediate **I**) will simultaneously attack the β -carbon followed by the loss of nitrate ion (as NaNO_3) to give the bicyclic compound, and the methoxyl group becomes incorporated in the ring.

A possible reaction pathway for the C-C bond-cleavage reaction being with the formation of the methoxy adduct **II** and the back-donation of the electron on the oxygen, followed by the loss of methyl formate to yield the final product **10**.

Conclusion

A facile C-C bond-cleavage reaction has been found, involving the reaction of the nitrate of 6-hydroxymethylpyrimidine derivatives with sodium alkoxide, or the reaction of 6-bromomethylpyrimidine derivatives with the sodium salt of 2-nitropropane. The former reaction is better than the latter for the formation of C-C bond-cleavage products. A plausible reaction mechanism is presented, in which 6-formyl compounds are key intermediates to the final products (bicyclic compound and C-C bond-cleavage product).

Experimental

General Melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. The IR spectra were taken with a JASCO IR-810 spectrophotometer. The UV spectra were measured on a Hitachi 323 or a Shimadzu UV-300 spectrophotometer in EtOH. The NMR spectra were taken on a Hitachi R-600 (60 MHz for ^1H), a JEOL JNM FX-90Q (90 MHz for ^1H , 22.5 MHz for ^{13}C), and a JEOL JNM GX-400 (400 MHz for ^1H , 100 MHz for ^{13}C) Fourier-transform spectrometer, and were measured in CDCl_3 solution unless otherwise mentioned. Chemical shifts are reported in ppm (δ) relative to tetramethylsilane as an internal standard. The MS were obtained on a JEOL JMS-DX-303 instrument equipped with a JMA-DA-5000 data processor.

General Reaction Procedure for Bromine-Substituted Compounds with Sodium Methoxide and 2-Nitropropane (Method A) A mixture of sodium

methoxide and 2-nitropropane in methanol was added to a solution of a bromo-substituted compound in methanol. The mixture was stirred at room temperature for 3 h. After removal of the solvent *in vacuo*, a small amount of water was added to the residue and the mixture was extracted with CHCl_3 (3 times). The combined extract was dried over MgSO_4 and filtered. The filtrate was concentrated to dryness. The product was purified by recrystallization from a suitable solvent.

General Reaction Procedure for 6-Pyrimidinylmethyl Nitrate with Sodium Methoxide (Method B) A solution of sodium methoxide and 6-pyrimidinylmethyl nitrate in methanol was stirred at room temperature for 3 h. The reaction mixture was treated as described in method A as above.

General Reaction Procedure and Computation of the Products Ratio (Tables I, II, and III) A solution of starting material (1 eq means 2.0 mmol) and sodium methoxide (2.0 mmol/ml in methanol) in methanol (entire volume, 30 ml) was stirred at room temperature for 3 h. The solvent was removed *in vacuo* at room temperature. The residue was dissolved in water (20 ml) and the mixture was extracted with CHCl_3 (3 times). The combined extract was dried over MgSO_4 and filtered. The filtrate was passed through a short silica gel column (Wako-gel C-200, 5 g, inner diameter 17 mm) eluted with a mixture of CHCl_3 - CH_3CN (gradient from 9:1 to 8:2). The eluent was concentrated to dryness *in vacuo*. The residue was subjected to determination of the products ratio by the following methods.

Computation by NMR (Table I): A part of the residue was dissolved in CDCl_3 and the NMR spectrum was recorded. Integration intensities of characteristic peaks [C(6)- CH_2 - for **1a**, C(6)-CHO for **2** and **5a**, and C(6)-H for **3** and **6a**] were computed and the meanvalues from three experiments are shown.

Computation by IATROSCAN (Tables II and III): The residue was dissolved in CHCl_3 (20 ml). The solution was placed on a Chromatrod-S III (silica gel rod, 5 rods were used for each measurement) and developed with a mixture of CHCl_3 - CH_3CN (20:1). The rods were measured using an IATROSCAN MK-5 (Iatron Laboratories, Inc.) equipped with a Chromatopack CR-6A (Shimadzu). Each reaction was carried out twice under the same reaction conditions and the product ratio was computed.

(5-Bromo-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-6-yl)-methyl Nitrate (1b) A solution of AgNO_3 (2.72 g, 16.0 mmol) in CH_3CN (30 ml) was added to a solution of **1a** (4.99 g, 13.0 mmol) in CH_3CN (70 ml). The mixture was heated at 90–95 °C for 2 h. The resulting crystalline mass was filtered off and the filtrate was washed with brine. The separated white mass was filtered off and the filtrate was dried over MgSO_4 . After removal of the solvent *in vacuo*, the residue was recrystallized from CH_3OH to give colorless prisms (4.23 g, 90%), mp 104–105 °C. *Anal.* Calcd for $\text{C}_7\text{H}_8\text{BrN}_3\text{O}_5$: C, 28.59; H, 2.74; Br, 27.17; N, 14.29. Found: C, 28.84; H, 2.67; Br, 26.92; N, 14.49. IR (KBr): 1708, 1670 (C=O), 1608, 1360, 1280 (ONO_2) cm^{-1} . UV λ_{max} nm (log ϵ): 292 (3.95). $^1\text{H-NMR}$ (90 MHz) δ : 3.39 (3H, s, N- CH_3), 3.52 (3H, s, N- CH_3), 5.67 (2H, s, C(6)- CH_2). EI-MS m/z (relative intensity in %): 295 (M^+ for ^{81}Br , 85.0), 293 (M^+ for ^{79}Br , 85.0), 162 (100).

5-Bromo-6-formyl-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione (2) This compound had a melting point of 84–86 °C; yield 78% (Table II), colorless plates (*n*-hexane-ether). *Anal.* Calcd for $\text{C}_7\text{H}_7\text{BrN}_2\text{O}_5$: C, 34.03; H, 2.86; Br, 32.34; N, 11.34. Found: C, 34.02; H, 2.77; Br, 32.11; N, 11.40. IR (KBr): 1702, 1650 (C=O) cm^{-1} . UV λ_{max} nm (log ϵ): 211 (3.98), 285 (3.94). $^1\text{H-NMR}$ (90 MHz) δ : 3.46 and 3.55 (each 3H, s, N- CH_3), 10.18 (1H, s, C(6)-CHO). EI-MS m/z (relative intensity in %): 248 (M^+ for ^{81}Br , 77.6), 246 (M^+ for ^{79}Br , 77.5).

5-Bromo-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione (3) This compound had a melting point of 184–185 °C; yield 80% (Table II), colorless needles (CH_3OH) [lit.⁸⁾ mp 181–182 °C (H_2O)]. $^1\text{H-NMR}$ (90 MHz) δ : 3.39 and 3.41 (each 3H, s, N- CH_3), 7.51 (1H, s, C(6)-H). EI-MS m/z (relative intensity in %): 220 (M^+ for ^{81}Br , 80.0), 218 (M^+ for ^{79}Br , 80.6).

5-Bromo-1-(3-bromopropyl)-6-formyl-3-methyl-2,4(1H,3H)-pyrimidinedione (5a) This compound was obtained as a viscous oil, yield 45%. IR (neat): 1707, 1658 br (C=O) cm^{-1} . UV λ_{max} nm (log ϵ): 210 (3.95), 283 (3.91). $^1\text{H-NMR}$ (90 MHz) δ : 2.28 (2H, m, $-\text{CH}_2-$), 3.44 (2H, t, $J=6.6$ Hz, Br- CH_2), 3.45 (3H, s, N- CH_3), 4.17 (2H, t, $J=6.6$ Hz, N- CH_2), 10.19 (1H, s, CHO). EI-MS m/z (relative intensity in %): 356 (M^+ for $2 \times ^{81}\text{Br}$, 11.7), 354 (M^+ for ^{81}Br and ^{79}Br , 23.2), 352 (M^+ for $2 \times ^{79}\text{Br}$, 12.1). HR-MS Calcd for $\text{C}_9\text{H}_{10}\text{Br}_2\text{N}_2\text{O}_5$ m/z : 355.9017 (for $2 \times ^{81}\text{Br}$), 353.9038 (for ^{79}Br and ^{81}Br), 351.9058 (for $2 \times ^{79}\text{Br}$). Found: 355.9006, 353.9045, 351.9048.

3-(5-Bromo-6-formyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)propyl Nitrate (5b) This compound had a melting point of 87–89 °C; yield 82% (Table II), yellow needles (hexane- CH_2Cl_2). *Anal.* Calcd for

$\text{C}_9\text{H}_{10}\text{BrN}_3\text{O}_6$: C, 32.17; H, 3.00; Br, 23.78; N, 12.50. Found: C, 32.13; H, 2.87; Br, 23.48; N, 12.54. IR (KBr): 1717, 1660 (C=O), 1623, 1355, 1277 (ONO_2) cm^{-1} . UV λ_{max} nm (log ϵ): 207 (4.00), 281 (3.95). $^1\text{H-NMR}$ (90 MHz) δ : 2.17 (2H, m, $-\text{CH}_2-$), 3.45 (3H, s, N- CH_3), 4.16 (2H, t, $J=7.1$ Hz, N- CH_2), 4.56 (2H, t, $J=6.1$ Hz, $\text{O}_2\text{NO}-\text{CH}_2$), 10.20 (1H, s, CHO). EI-MS m/z (relative intensity in %): 337 (M^+ for ^{81}Br , 80.9), 335 (M^+ for ^{79}Br , 83.6).

5-Bromo-1-(3-bromopropyl)-3-methyl-2,4(1H,3H)-pyrimidinedione (6a) This compound had a melting point of 74–75 °C; yield 85% (Table I), colorless needles (ether). *Anal.* Calcd for $\text{C}_8\text{H}_{10}\text{Br}_2\text{N}_2\text{O}_5$: C, 29.47; H, 3.09; Br, 49.02; N, 8.59. Found: C, 29.51; H, 3.03; Br, 48.79; N, 8.59. IR (KBr): 1713, 1660 (C=O) cm^{-1} . UV λ_{max} nm (log ϵ): 212 (3.97), 283 (3.97). $^1\text{H-NMR}$ (90 MHz) δ : 2.28 (2H, m, $-\text{CH}_2-$), 3.40 (3H, s, N- CH_3), 3.45 (2H, t, $J=6.2$ Hz, Br- CH_2), 3.96 (2H, t, $J=6.7$ Hz, N- CH_2), 7.61 (1H, s, C(6)-H). EI-MS m/z (relative intensity in %): 327 (M^+ for $2 \times ^{81}\text{Br}$, 49.2), 325 (M^+ for ^{81}Br and ^{79}Br , 100.0), 323 (M^+ for $2 \times ^{79}\text{Br}$, 52.5).

3-(5-Bromo-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)propyl Nitrate (6b) This compound had a melting point of 88–90 °C; yield 78% (Table II), colorless needles (MeOH). *Anal.* Calcd for $\text{C}_8\text{H}_{10}\text{BrN}_3\text{O}_5$: C, 31.19; H, 3.27; Br, 25.94; N, 13.64. Found: C, 31.23; H, 3.14; Br, 25.68; N, 13.70. IR (KBr): 1705, 1677, 1660 (C=O), 1605, 1340, 1275 (ONO_2) cm^{-1} . UV λ_{max} nm (log ϵ): 207 (3.98), 280 (3.93). $^1\text{H-NMR}$ (90 MHz) δ : 2.18 (2H, m, $-\text{CH}_2-$), 3.40 (3H, s, N- CH_3), 3.91 (2H, t, $J=7.0$ Hz, N- CH_2), 4.54 (2H, t, $J=5.9$ Hz, $\text{O}_2\text{NO}-\text{CH}_2$), 7.54 (1H, s, C(6)-H). EI-MS m/z (relative intensity in %): 309 (M^+ for ^{81}Br , 36.7), 307 (M^+ for ^{79}Br , 36.6).

2-(5-Bromo-6-formyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)ethyl Nitrate (8) This compound had a melting point of 87–88 °C; yield 67% (Table III), pale yellow needles (ether). *Anal.* Calcd for $\text{C}_8\text{H}_8\text{BrN}_3\text{O}_6$: C, 29.83; H, 2.50; Br, 24.81; N, 13.05. Found: C, 30.01; H, 2.48; Br, 24.64; N, 13.12. IR (KBr): 1705, 1660 (C=O), 1618, 1440, 1288 (ONO_2) cm^{-1} . UV λ_{max} nm (log ϵ): 206 (4.00), 281 (3.94). $^1\text{H-NMR}$ (90 MHz) δ : 3.46 (3H, s, N- CH_3), 4.55 (2H, m, $\text{O}_2\text{NO}-\text{CH}_2$), 4.69 (2H, m, N- CH_2), 10.17 (1H, s, CHO). EI-MS m/z (relative intensity in %): 323 (M^+ for ^{81}Br , 26.7), 321 (M^+ for ^{79}Br , 26.6).

2-(5-Bromo-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)ethyl Nitrate (10) A mixture of **7** (1.0 g, 2.7 mmol) and tetraethylammonium chloride (45 mg, 0.27 mmol) in 40% NaOH (aq., 1.1 ml) and CHCl_3 (10 ml) was stirred at room temperature for 5.5 h. After completion of the reaction, the mixture was separated and the aqueous layer was extracted with CHCl_3 (3 times). The combined extract was dried over MgSO_4 and filtered. The solvent was removed from the filtrate and the crystalline residue was recrystallized from benzene to give 0.72 g (91%) of colorless prisms, mp 130–131 °C. *Anal.* Calcd for $\text{C}_7\text{H}_8\text{BrN}_3\text{O}_5$: C, 28.59; H, 2.74; Br, 27.17; N, 14.29. Found: C, 28.73; H, 2.78; Br, 27.03; N, 14.13. IR (KBr): 1715, 1665, 1640 (C=O), 1280 ($\text{O}-\text{NO}_2$) cm^{-1} . UV λ_{max} nm (log ϵ): 206 (4.02), 278 (3.93). $^1\text{H-NMR}$ (90 MHz) δ : 3.41 (3H, s, N- CH_3), 4.10 (2H, dd, $J=4.0$, 5.3 Hz, N- CH_2), 4.73 (2H, dd, $J=4.0$, 5.3 Hz, $\text{O}_2\text{NO}-\text{CH}_2$), 7.49 (1H, s, C(6)-H). EI-MS m/z (relative intensity in %): 295 (M^+ for ^{81}Br , 22.5), 293 (M^+ for ^{79}Br , 22.8), 219 (($\text{M}-\text{CH}_2\text{ONO}_2$) $^+$ for ^{81}Br , 47.7), 217 (($\text{M}-\text{CH}_2\text{ONO}_2$) $^+$ for ^{79}Br , 48.8), 162 ((219 and 217- CH_2NCO) $^+$ for ^{81}Br , 99.3), 160 ((219 and 217- CH_2NCO) $^+$ for ^{79}Br , 100.0).

References

- 1) T. Kinoshita, Y. Watanabe, Y. Takaishi, T. Okunaka, S. Nakao, S. Furukawa, *Chem. Pharm. Bull.*, **41**, 1485 (1993).
- 2) a) N. Kornblum, "The Chemistry of Functional Groups," Part 1, ed. by S. Patai, John Wiley and Sons, 1982, pp. 361–393; b) H. B. Hass, M. L. Bender, *J. Am. Chem. Soc.*, **71**, 1767 (1949).
- 3) T. Kinoshita, M. Uga, Y. Tanimoto, K. Ohishi, S. Furukawa, *Chem. Pharm. Bull.*, **40**, 2668 (1992).
- 4) T. Kinoshita, Y. Takaishi, T. Okunaka, T. Ohwada, S. Furukawa, *J. Heterocycl. Chem.*, **29**, 741 (1992).
- 5) T. Kinoshita, T. Okunaka, T. Ohwada, H. Kawanaka, S. Furukawa, *J. Heterocycl. Chem.*, **28**, 1901 (1991).
- 6) a) N. Kornblum, H. W. Frazir, *J. Am. Chem. Soc.*, **88**, 865 (1966); b) A. J. Boulton, A. McKillop, "Comprehensive Heterocyclic Chemistry," ed. by A. R. Katritzky, C. W. Rees, Vol. 2, ed. by A. J. Boulton, A. McKillop, Pergamon Press, Oxford, 1984, pp. 52–53; B. C. Uff, *ibid.*, Vol. 2, pp. 339–340; c) D. J. Brown, *ibid.*, Vol. 3, ed. by A. J. Boulton, A. McKillop, 1984, pp. 80–82.
- 7) K. Hirota, Y. Yamada, Y. Kitada, S. Senda, *J. Chem. Soc., Perkin Trans. 1*, **1981**, 2943.
- 8) "Beilsteins Handbuch der Organischen Chemie, Hauptwerk," Vol. 24, 1936, p. 319.